- Report
- March 2024
- 196 Pages
Global
From €3241EUR$3,374USD£2,790GBP
€3601EUR$3,749USD£3,100GBP
- Report
- February 2024
- 250 Pages
Global
From €4802EUR$5,000USD£4,134GBP
- Report
- November 2023
- 144 Pages
Global
From €2400EUR$2,499USD£2,066GBP
- Report
- August 2022
- 30 Pages
Global
From €2641EUR$2,750USD£2,274GBP
- Report
- August 2022
Global
From €4322EUR$4,500USD£3,721GBP
- Report
- July 2018
- 765 Pages
Global
From €21130EUR$22,000USD£18,192GBP
- Report
- December 2019
- 356 Pages
Global
From €10560EUR$10,995USD£9,092GBP
- Report
- July 2018
- 27 Pages
Global
From €9605EUR$10,000USD£8,269GBP
- Report
- May 2020
- 151 Pages
Global
From €5158EUR$5,370USD£4,440GBP
- Report
- April 2023
- 147 Pages
Global
From €5762EUR$5,999USD£4,961GBP
Tysabri is a drug used to treat multiple sclerosis (MS) and Crohn's disease. It is a monoclonal antibody that works by blocking the action of a protein called alpha-4-integrin, which is involved in the inflammatory process. Tysabri is a central nervous system (CNS) drug, meaning it is used to treat diseases of the brain and spinal cord. It is administered intravenously and is usually given once every four weeks.
Tysabri is a relatively new drug, having been approved by the U.S. Food and Drug Administration (FDA) in 2004. It is used to treat both relapsing-remitting MS and Crohn's disease, and is considered to be a highly effective treatment for both conditions.
The Tysabri market is made up of a number of companies, including Biogen, Elan Pharmaceuticals, and Genentech. These companies are involved in the research, development, and marketing of Tysabri. They are also responsible for the production and distribution of the drug. Show Less Read more
